The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000900314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
28/05/2026
Date registered
Help: Date registered
21/07/2026
Date last updated
Help: Date last updated
21/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
21/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Changes for Australian Paediatric Patients In the Treatment of Acute Lymphoblastic Leukaemia (CAPITALL), A comparison study measuring the effectiveness of an alternative treatment schedule incorporating earlier blinatumomab and standard treatment.
Scientific title
Changes for Australian Paediatric Patients In the Treatment of Acute Lymphoblastic Leukaemia (CAPITALL), A comparison study measuring the effectiveness of an alternative treatment schedule incorporating earlier blinatumomab and standard treatment.
Additional trial identifiers [1] 317421 0
Nil
Universal Trial Number (UTN)
Trial acronym
CAPITALL (Changes for Australian Paediatric Patients In the Treatment of Acute Lymphoblastic Leukaemia)
Related trial records

Health condition
Health condition(s) studied:
Acute Lymphoblastic Leukaemia 342089 0
Condition category
Condition code
Cancer 338209 338209 0 0
Leukaemia - Acute leukaemia
Cancer 338210 338210 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The purpose of this study is to evaluate the effects of introducing blinatumomab earlier in treatment for paediatric patients with acute lymphoblastic leukaemia (ALL), compared with the current standard treatment schedule. The study will compare leukaemia clearance, treatment outcomes, and overall treatment burden between the two treatment approaches.

Patients will be stratified into risk groups as with standard treatment (standard, medium and high risk). Patients are stratified using a clinical, genetic and molecular response criteria at diagnosis and at specified timepoints throughout treatment.

This is not a randomised study and most patients will receive blinatumomab during their treatment, not including standard risk patients (as per standard treatment).

Patients on the CAPITALL study will have complete assessments and have their medical records reviewed. We will compare the results of patients treated on CAPITALL with those of patients recently treated at our hospitals using the standard treatment regime.

This trial uses only approved drugs and will have a focus on blinatumomab.

Blinatumomab is given in blocks (1-3) depending on the patients risk stratification and determined treatment plan.

Blinatumomab Dose: 15mcg/m2/day (maximum dose 28 mcg/day)
Blinatumomab Duration: 28 days
Blinatumomab Mode: Continuous 28 day Intravenous Infusion

On this study patients will receive the following treatment blocks based on their risk stratification in the order listed below:

Standard Risk: Induction, Consolidation, Protocol M, Protocol III and Maintenance. This is the exact course of treatment as per standard of care.

Medium Risk: Induction, Blinatumomab Block 1, Consolidation, Protocol M, Protocol II, Blinatumomab Block 2 and Maintenance.

High Risk: Induction, Blinatumomab Block 1, Consolidation, High Risk Course 1, then either High Risk Blinatumomab Blocks 2 & 3 or alternatively High Risk Course 2 & 3 (for patients who don’t respond as well to Blinatumomab), Protocol III and Maintenance.


All patients regardless of risk stratification will be on treatment for at least 2 years from the start of Induction.
Intervention code [1] 334214 0
Treatment: Drugs
Description of the comparator or control
It is the current standard of care for patients with B-ALL in Australia to receive the following treatment blocks:
• Standard Risk (SR): Induction, Consolidation, Protocol M, Protocol II, Maintenance
• Medium Risk (MR): Induction, Consolidation, Blinatumomab Block 1, Protocol M, Protocol II, Blinatumomab Block 2, Maintenance
• High Risk (HR): Induction, Consolidation, Blinatumomab Block 1, High Risk Course 1 (HR1), Blinatumomab Block 2, Blinatumomab Block 3, Protocol II, Maintenance

The treatment blocks consist of the following treatment:

Induction: Involves intravenous infusion of vincristine (days 8, 16, 22 &29), daunorubicin (days 8, 16, 22* & 29*), peg asparaginase (Days 12 & 26) and oral administration of prednisolone daily for over 5 weeks. Intrathecal doses of methotrexate will be given on days 1, 15 & 33 (only for patients with Central Nervous System (CNS) disease)
*MR & HR patients only

Consolidation: Spilt into Consildation A, B Short & B Extended. Consilidation A involves oral administration of mercaptopurine daily for 2 weeks, subcutaneous (or intravenous) administration of cytarabine over two 4-day treatment blocks (Days 1-4 and 8-11), and an intrathecal dose of methotrexate on Day 8. Consolidation B Short is given immediately after Consolidat A and to SR & MR patients only. It involves intravenous infusion of cyclophosphamide (days 15 and 29), oral administration of mercaptopurine daily for 2 weeks, subcutaneous (or intravenous) administration of cytarabine over two 4-day treatment blocks (Days 15-18 and 22-25), and an intrathecal dose of methotrexate on Day 22. Consolidation B Extended is given instead of Consolidation B Short for HR patients. It involves oral (or intravenous) administration of dexamethasone daily for 1 week, intravenous infusion of vincristine (days 15, 22), peg-asparaginase (day 15) and cyclophosphamide (days 30, 43), oral administration of mercaptopurine daily for 2 weeks , subcutaneous (or intravenous) administration of cytarabine over two 4-day treatment blocks (Days 29-32 and 36-39), and an intrathecal dose of methotrexate on Day 29.


Protocol M: Involves oral administration of mercaptopurine daily for 8 weeks (days 1-56), intravenous infusion of high-dose methotrexate over 24 hour (days 8, 22, 36 & 50), and intrathecal administration of methotrexate (days 8, 22, 36 & 50).

Protocol II: Split into Protocol IIA & IIB. Protocol IIA involves oral (or intravenous) administration of dexamethasone daily for30 days, intravenous infusion of vincristine (days 8, 15, 22 &29), doxorubicin (Days 8, 15, 22 & 29) and peg-asparaginase (day 8), with intrathecal administration of methotrexate (day 1 & 18 for HR CNS patients only). Protocol IIB involves intravenous infusion of cyclophosphamide on day 37, subcutaneous (or intravenous) administration of cytarabine over two 4-day treatment blocks (days 36-39 and 43-46), oral administration of thioguanine daily for 2 weeks, and intrathecal administration of methotrexate (days 36 & 43).

Protocol III: Split into Protocol IIIA & IIIB, Protocol IIIA involves oral (or intravenous) administration of dexamethasone daily for 23 days, intravenous infusion of vincristine (days 1 & 8), doxorubicin (days 1 * 8), and peg-asparaginase (day 1). Protocol IIIB involves intravenous infusion of cyclophosphamide (day 16), subcutaneous (or intravenous) administration of cytarabine over two 4-day treatment blocks (days 15-18 and 22-25), oral administration of thioguanine daily for 2 weeks, and intrathecal administration of methotrexate (days 15 & 22).

Blinatumomab Blocks: Involves a continuous intravenous infusion of blinatumomab over a 28 day course.

High Risk Course 1: Involves oral (or intravenous) administration of dexamethasone daily for 5 days, intravenous infusion of high-dose methotrexate over 24 hours (day 1), vincristine (days 2 & 6), cyclophosphamide every 12 hours (days 2–4), high-dose cytarabine every 12 hours (day 5), and peg-asparaginase (day 6), intrathecal administration of methotrexate on day 1 (Additional on day 5 for CNS patients).

Maintenance: Involves oral administration of mercaptopurine daily and methotrexate once weekly for the duration over 2 years from diagnosis.

The CAPITALL trial will study earlier administration of blinatumomab (prior to consolidation for MR & HR patients) compared to this current standard of care.

Specific data from this study will be compared to data collected during the Associazione Italiana Ematologia Oncologia Pediatrica - Berlin-Frankfurt-Münster (AIEOP-BFM) Acute Lymphoblastic Leukaemia (ALL) 2009 (NCT01117441) and 2017 (NCT03643276) studies which follow the current standard of care regime.
Control group
Historical

Outcomes
Primary outcome [1] 345570 0
To assess the Polymerase Chain Reaction - Measurable Residual Disease (PCR-MRD) of 28-day course of blinatumomab delivered post Induction therapy in non-Standard Risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) participants when compared to the historical control cohorts on AIEOP-BFM ALL 2017 and 2009
Timepoint [1] 345570 0
- Pre-Treatment (Diagnosis). - Day 33 of Induction (Applicable for all patients). - End of Blinatumomab Block 1 (Applicable for all non-SR patients). - End of Consolidation (Applicable for all non-SR patients).
Secondary outcome [1] 462201 0
To evaluate the proportion of participants classified as high risk based on treatment response compared to historical controls
Timepoint [1] 462201 0
- Pre-Treatment/baseline (Diagnosis). - Day 33 of Induction (Applicable for all patients). - End of Blinatumomab Block 1 (Applicable for all non-SR patients). - End of Consolidation (Applicable for all non-SR patients).
Secondary outcome [2] 462202 0
To assess the 5-year event free survival (EFS) and overall survival (OS) compared to historical controls. This will be assessed as a composite outcome,
Timepoint [2] 462202 0
End of maintenance treatment and a period of 5 years for follow up
Secondary outcome [3] 462203 0
To determine the rates of cytokine release syndrome and neurotoxicity when blinatumomab is delivered post induction. This will be assessed as a composite outcome.
Timepoint [3] 462203 0
AE collection will be ongoing throughout the study from the signing of consent until 30 days after the last dose of treatment (end of maintenance therapy).
Secondary outcome [4] 462204 0
To assess the rates of targeted toxicities (culture-positive infection, sepsis, unplanned readmission to hospital) and mortality in Consolidation compared to historical controls. This will be assessed as a composite outcome.
Timepoint [4] 462204 0
AE collection will be ongoing throughout the study from the signing of consent until 30 days after the last dose of treatment (end of maintenance therapy).
Secondary outcome [5] 462205 0
To prospectively evaluate patient-reported outcomes to characterise the acceptability of treatment for children and their families.
Timepoint [5] 462205 0
SSPedi data will be collected at the following timepoints: - After Induction (Applicable for all patients) - After Blinatumomab Block 1 (Applicable for all non-SR patients) - Throughout Consolidation (Applicable for all patients) Quality of life will be monitored monthly for the first year of treatment
Secondary outcome [6] 462206 0
To describe the kinetics of B-cell recovery IgG levels after receiving blinatumomab, and monitor the role of IVIg replacement in those with hypogammaglobulinemia. This will be assessed as a composite outcome.
Timepoint [6] 462206 0
All patients will have their B-Cells tested at the following timepoints: - Baseline (Pre Blinatumomab Block 1) - 1 monthly on treatement (all treatment blocks) - End of treatment (end of maintenance treatment) - 3 years following end of treatment (end of maintenance treatment) Patients diagnosed with hypogammaglobulinemia (low levels of antibodies) and receiving IgG replacement will have their B-Cells tested at the additional timepoints: - Monthly after diagnosis of hypogammaglobulinemia - 3 monthly following recovery of hypogammaglobulinemia
Secondary outcome [7] 462207 0
To study the feasibility and tolerability of routine vitamin D screening and supplementation for deficiency in a prospective cohort of Australian B ALL participants. This will be assessed as a composite outcome
Timepoint [7] 462207 0
Vitamin D levels will be tested at the following timepoints: - Pre-Treatment (Diagnosis) - Every 3 months on intensive treatment (all treatment blocks excluding maintenance) - Every 6 months on maintenance therapy - Yearly off treatment AE collection will be ongoing throughout the study from the signing of consent until 30 days after the last dose of treatment (end of maintenance treatment).
Secondary outcome [8] 462208 0
To evaluate the impact on participant quality of life when receiving blinatumomab vs chemotherapy as measured by patient reported outcomes
Timepoint [8] 462208 0
Quality of life will be monitored monthly for the first year of overall treatment (regardless of treatment block)
Secondary outcome [9] 463857 0
To prospectively evaluate patient-reported outcomes to characterise the burden of treatment for children and their families.
Timepoint [9] 463857 0
Quality of life will be monitored through surveys monthly for the first year of overall treatment (regardless of treatment block). Treatment burden interviews will be conducted at the same timepoints.

Eligibility
Key inclusion criteria
Each patient must meet all of the following criteria to be enrolled in this trial:
• Patient must provide a signed and dated informed consent form or have a legally acceptable representative capable of understanding the informed consent document and providing consent on the patient’s behalf.
• Patients must be newly diagnosed with B-cell acute lymphoblastic leukaemia or newly diagnosed non-KMT2A rearranged infant (<12month old) ALL.
• Age <18 years on the day of diagnosis.
• Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to initiation of treatment, agree to use adequate contraception during the study and for 12 months following completion of anti-leukaemic therapy.
Minimum age
12 Months
Maximum age
18 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Patients meeting any of the following criteria will be excluded from the trial:
• Patients with Ph+ (BCR-ABL1 or t(9;22) positive) ALL.
• Patients with CD19 -negative precursor B ALL at diagnosis.
• Patients with Mixed phenotype acute leukaemia (MPAL), undifferentiated leukaemia or biphenotypic leukaemia.
• Infants <12mo with KMT2A rearranged ALL.
• Patients with B cell lymphoblastic lymphoma.
• Pre-treatment with ?1mg/kg/day prednisone equivalent for more than 2 weeks during the last month before diagnosis.
• Pre-treatment with other cytotoxic agents or following another protocol.
• Patients with an underlying disease, condition or circumstance that will interfere with ability to deliver treatment according to the protocol.
• Pregnant or nursing (lactating) females.
• Live vaccine immunisation within 2 weeks before start of protocol treatment.
• Sexually active patients not willing to use highly effective contraceptive method until 12 months after the end of anti-leukaemic therapy.
The following additional exclusion criteria apply to non-SR patients who would be ineligible for blinatumomab treatment and thus taken off study:
• Patients with significant CNS pathology that would preclude treatment with blinatumomab, including a history of severe neurologic disorder or autoimmune disease with CNS involvement.
• Evidence of active CNS ALL at time of blinatumomab. Patients with CNS disease present at diagnosis which has cleared remain eligible.
• Patients with uncontrolled HIV infection.
• Known hypersensitivity to immunoglobulins.

Patients who are not enrolled on treatment prior to Day 12 of induction treatment will not be eligible.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Specific data from this study will be compared to previous data collected during the Associazione Italiana Ematologia Oncologia Pediatrica - Berlin-Frankfurt-Münster (AIEOP-BFM) Acute Lymphoblastic Leukaemia (ALL) 2009 and 2017 studies which follow the current standard of care regime.
Phase
Phase 4
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29553 0
Sydney Children's Hospital - Randwick
Recruitment hospital [2] 29554 0
The Children's Hospital at Westmead - Westmead
Recruitment postcode(s) [1] 45876 0
2031 - Randwick
Recruitment postcode(s) [2] 45877 0
2145 - Westmead

Funding & Sponsors
Funding source category [1] 321994 0
Hospital
Name [1] 321994 0
Kids Cancer Centre
Country [1] 321994 0
Australia
Primary sponsor type
University
Name
University of New South Wales - Sydney
Address
Country
Australia
Secondary sponsor category [1] 324869 0
None
Name [1] 324869 0
Address [1] 324869 0
Country [1] 324869 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320528 0
Sydney Children's Hospitals Network Human Research Ethics Committee
Ethics committee address [1] 320528 0
Ethics committee country [1] 320528 0
Australia
Date submitted for ethics approval [1] 320528 0
26/06/2026
Approval date [1] 320528 0
Ethics approval number [1] 320528 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150762 0
Dr Richard Mitchell
Address 150762 0
Health Translation Hub, Sydney Children’s Hospital High Street, Randwick NSW 2031 Australia
Country 150762 0
Australia
Phone 150762 0
+61 2 93821733
Fax 150762 0
Email 150762 0
Contact person for public queries
Name 150763 0
Richard Mitchell
Address 150763 0
Health Translation Hub, Sydney Children’s Hospital High Street, Randwick NSW 2031 Australia
Country 150763 0
Australia
Phone 150763 0
+61 2 93821789
Fax 150763 0
Email 150763 0
Contact person for scientific queries
Name 150764 0
Richard Mitchell
Address 150764 0
Health Translation Hub, Sydney Children’s Hospital High Street, Randwick NSW 2031 Australia
Country 150764 0
Australia
Phone 150764 0
+61 2 93821789
Fax 150764 0
Email 150764 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Results will be published in accredited scientific journals. This will be distributed and explained to participants who wish to receive study results by their treating doctor.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.